Sakhanda Wire
NVDA $153.59 -1.64% MSFT $507.00 -2.12% GOOGL $279.98 -1.32% META $619.94 -1.03% AMZN $256.62 -0.44%
← Back to the news

Novo Nordisk expands AWS AI use in drug discovery

Novo Nordisk is expanding its use of Amazon Web Services artificial intelligence tools in drug research under a new agreement that makes AWS the company’s preferred cloud provider and strategic AI partner. The companies are establishing a co-innovation hub at Novo Nordisk’s existing London facility, bringing together its researchers with AWS engineers, AI specialists, applied scientists and professional services teams.

The partners plan to use AI agents and Amazon Bio Discovery for tasks including identifying drug targets, designing therapies and analysing biological data. The service provides access to more than 40 biological AI models and can coordinate models in multi-step workflows. Novo Nordisk also intends to connect computational analysis with laboratory synthesis and testing, then feed experimental results back into the research process. Amazon Bedrock will support applications using clinical, genomic and imaging data.

Novo Nordisk already uses Bedrock-based generative AI across the organisation. AWS says more than 25,000 employees have used a platform supporting over 2,500 use cases. In one clinical-documentation application using Anthropic’s Claude 3.5, generation time fell by more than 90%, while medical professionals continued to review the output. The new agreement extends AI use into drug-development and operational workflows.

Written by Sakhanda Wire AI from reporting by AI News. Facts, quotes and full context are in the original article below.

Originally published by AI News on

Read the original on AI News ↗

The reporting and the image belong to AI News and are credited and linked above; the text on this page is Sakhanda Wire's own summary.

← Back to the news

More stories

All the latest news